Companies: 10,795·Total market cap: $144.5T
Royalty Pharma plc

Royalty Pharma plc

RPRXNASDAQHealthcare● Active
$55.94
+$0.07(+0.12%)
Market Cap$24.1B
P/E Ratio—
52W High$56.5
52W Low$33.37
SEC Filings

Royalty Pharma plc (RPRX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001802768 · RPRX · NASDAQ · as of Jun 8, 2026

Filing snapshot

593
Total Filings
8-K
Latest Form
2026-06-04
Most Recent
2020
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001802768 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-11
Fiscal Year End
Feb 11, 2026
Accession No.
0001802768-26-000003
Primary Document
rprx-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001802768 · Accession 0001802768-26-000003

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-06
View 10-Q on SEC
8-KCurrent Report
8-K
2026-06-04Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-04
View
8-KCurrent Report
8-K
2026-05-28
View
13F-NT13F-NT
13F-NT
2026-05-14
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-14
View
10-QQuarterly Report
10-Q
2026-05-06
View
8-KCurrent Report
8-K
2026-05-06
View
8-KCurrent Report
8-K
2026-04-13
View
ARSARS
ARS
2026-04-10
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-10
View
DEF 14AProxy Statement
DEF 14A
2026-04-10
View
13F-NT13F-NT
13F-NT
2026-04-01
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-02-20
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-13
View
10-KAnnual Report
10-K
2026-02-11
View
8-KCurrent Report
8-K
2026-02-11
View
Showing 1–15 of 263 filingsForm 4 / 144 hidden· 593 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001802768  |  Exchange: NASDAQ · Healthcare

Royalty Pharma plc (NASDAQ: RPRX) has submitted 593 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001802768, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Royalty Pharma plc's most comprehensive regulatory disclosure. The most recent Royalty Pharma plc 10-K was filed on 2026-02-11 for fiscal year ending 2026. Historical RPRX 10-K annual reports are available from 2020 through 2026.

Investors researching Royalty Pharma plc SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
UTHR SEC Filings →ROIV SEC Filings →INCY SEC Filings →HOLX SEC Filings →GMAB SEC Filings →THC SEC Filings →EXEL SEC Filings →SNN SEC Filings →
→ RPRX Financials→ RPRX Earnings→ RPRX Insider Trades

Frequently Asked Questions

RPRX SEC Filings · 8 questions

Royalty Pharma plc (RPRX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 593 filings and access original documents at no cost. Royalty Pharma plc's CIK is 0001802768.

RPRX SEC filingsRoyalty Pharma plc SEC documentsfind RPRX 10-K